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Abstract
Rationale—Bone marrow (BM) cells play an important role in physiologic and therapeutic
neovascularization. However, it remains unclear whether any specific uncultured BM cell
populations have higher angiogenic and vasculogenic activities. Moreover, there has been
controversy regarding the vasculogenic ability of BM cells.
Objective—Preliminary flow cytometric analysis showed that CD31, traditionally a marker for
endothelial cells, is expressed in certain non-endothelial BM mononuclear cells (MNCs) in both
human and mouse. Based on the conserved CD31 expression in the axis of hematopoietic stem/
progenitor cells (HSC/HPCs) to endothelial cells, we further sought to determine the
comprehensive vasculogenic and angiogenic characteristics of human and mouse BM-derived
CD31+ cells.
Methods and Results—Flow cytometric analysis demonstrated that all CD31+ cells derived
from BM were CD45+ and expressed markers for both HSC/HPCs and ECs. Comprehensive gene
expression analyses revealed that BM-CD31+ cells expressed higher levels of angiogenic genes
than CD31− cells. Endothelial progenitor cells, as well as HSC/HPCs, were almost exclusively
confined to the CD31+ cell fraction, and culture of CD31+ cells under defined conditions gave rise
to endothelial cells. Finally, injection of CD31+ cells into ischemic hindlimb repaired ischemia,
increased expression of angiogenic and chemoattractive factors, and in part directly contributed to
vasculogenesis, as demonstrated by both three-dimensional confocal microscopy and flow
cytometry.
Conclusions—These data indicate that BM-CD31+ cells represent highly angiogenic and
vasculogenic cells and can be a novel and highly promising source of cells for cell therapy to treat
ischemic cardiovascular diseases.
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Introduction
Formation of new blood vessels (neovascularization) consists of two processes,
vasculogenesis and angiogenesis. Vasculogenesis refers to the de novo development of
blood vessels from endothelial progenitor cells (EPCs) or angioblasts which differentiate
into endothelial cells (ECs). In contrast, angiogenesis is the formation of new vasculature
from preexisting blood vessels through proliferation, migration, and remodeling of
differentiated ECs. The identification of circulating EPCs in adult vertebrates suggested a
role for BM cells in postnatal vasculogenesis1–3, and led to trials of BM cells for therapy for
ischemic cardiovascular diseases. However, conflicting results from recent clinical trials4, 5
suggests a need for the discovery of new cell types6 and more thorough investigation of the
therapeutic mechanisms.
Two of the most important questions in current EPC biology are whether the reported
cultured EPCs or similar BM cells have true vasculogenic potential and whether a specific
marker can prospectively identify true EPCs or vasculogenic cells. The endothelial
differentiation or vasculogenic potential of early EPCs has been questioned7,3, 8–11. Since
various studies have used different cell types and animal models, it is difficult to directly
compare the results. Interestingly, a majority of the papers reporting the non-differentiation
of EPCs used MI models. Unique conditions of the heart, including the constant motion of
the myocardium and the high oxygen consumption of cardiomyocytes make sustained
survival of the transplanted cells more difficult. This could reduce the observed
differentiation, possibly masking true differentiation potential. While early EPCs are
isolated by relatively short-term culture of peripheral blood cells. a newer type of EPCs,
known as outgrowing ECs12, late EPCs13, or endothelial colony-forming cells (ECFCs)14,
can be derived from relatively long-term culture (more than 10 days). Cultured early EPC
and EPC-colony forming unit (CFU) are indeed angiogenic cells co-expressing myeloid and
endothelial markers in contrast to late EPC” or ECFC 14, 15. Moreover, to date, no markers
are unanimously accepted to define uncultured EPCs in circulation or BM in mice or
humans15.
It now seems that paracrine, or humoral, effects are the main mechanism responsible for the
therapeutic effects of BM-derived cell therapy for ischemic cardiovascular disease7, 16.
Since most of the cells used for previous studies were selected based upon their stem cell-
like or vasculogenic potential3, 17, 18, identification of cells with higher angiogenic or
paracrine activities is now necessary to improve therapeutic efficacy and to develop next
generation cell therapy for ischemic cardiovascular diseases. However, little research has
been conducted to identify cells having higher angiogenic effects. Based on the above
concerns and newly developed mechanistic findings, we sought to identify and isolate a
specific cell population which possesses higher angiogenic or paracrine activities, includes
vasculogenic cells and does not need ex vivo culture for identification or therapeutic use. In
pursuit of this goal, we found that CD31 appears to be a good marker for this purpose. CD31
(also known as platelet endothelial cell adhesion molecule-1) is a 130-kDa, type I
transmembrane glycoprotein, and is a member of the immunoglobulin gene superfamily.
CD31 is highly expressed on ECs and to different degrees on several hematopoietic cells,
including monocytes, granulocytes, and platelets19. Furthermore, CD31 is expressed in
lineage− Sca-1+c-Kit+ (LSK) mouse HSCs20, side population cells in mouse BM21, mouse
embryonic stem cells22, and human early EPCs7. However, the expression of CD31 in
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mouse HPCs and human HSCs has yet to be clearly investigated. Interestingly, HSCs/HPCs
were already known to have angiogenic and/or vasculogenic potential as well as favorable
cardiovascular regenerative effects18, 23, 24. This conserved expression of CD31 in the axis
of HSC/HPCs, EPCs and ECs has led us to investigate whether this group includes all the
necessary cells associated with neovascularization and may be beneficial for treating
ischemic cardiovascular diseases.
Methods
Animals
C57BL/6J mice, GFP-transgenic mice (C57BL/6J background) and athymic nude mice (The
Jackson Laboratory) were used. All protocols for animal experiments were approved by the
Institutional Animal Care and Use Committees of Caritas St. Elizabeth Medical Center and
Emory University.
Harvesting BM-mononuclear cells and CD31 selection
Human BM (hBM) from healthy adults was purchased from Lonza, and mouse BM (mBM)
cells were harvested as previously described 16. Mouse and human BM-MNCs were isolated
by density gradient centrifugation using Histopaque 1083 (Sigma) and Histopaque 1077
(Sigma), respectively. Mouse and human BM-CD31+ and CD31− cells were isolated using
magnetic columns (MACS®, Mitenyi Biotec).
Transplantation of the cells into ischemic hindlimb
Hindlimb ischemia was generated by ligation of the femoral artery and cauterization of large
branches17. One million mBM-CD31+ or mBM-CD31− cells in 100μl PBS were
intramuscularly injected into the ischemic hindlimb of C57BL/6J mice, and cells in 200 μl
PBS were intravenously injected into nude mice with ischemic hindlimb17, 25.
Details on the materials and methods, including the following items, can be found in the
online supplemental materials: microarray and gene set enrichment analysis26, colony
forming unit assay, BM transplantation, EPC culture assay1, 17, 27, induction of
differentiation of CD31+ cells into ECs in vitro, blood flow measurement in ischemic
hindlimbs, measurement of capillary density 16, histologic analysis, cell adhesion test, and
real-time RT-PCR16.
Results
Dual hematopoietic and endothelial cell characteristics of BM-CD31+ cells
To characterize the phenotype of mBM-CD31+ cells, we first isolated mBM-MNCs from
C57BL/6J mice and carried out flow cytometric analysis (Figure 1A). About 34% of mBM-
MNCs were found to expr ess CD31. Next, we determined which subsets of mBM-MNCs
express CD31 using antibodies specific to B- and T-lymphocytes, myelomonocytic cells,
and erythroid cells. FACS analysis showed that, on average, CD31 was expressed in 73% of
lineage-depleted (Lin−) cells, 53% of B- (B220+) lymphocytes, 42% of T- (CD3e+)
lymphocytes, 12% of erythroid cells (Ter-119+), 17% of CD11b+ myelomonocytic cells and
17% of Gr-1+ myelomonocytic cells (Figure 1B). Among myelomonocytic cells which
express CD11b or Gr-1, the rate of CD31 expression was higher in Ly-6g− cells (mainly
monocytes, 32%, data not shown) than in Ly-6g+ cells (mainly granulocytes, 4.4%, Figure
1B). Among CD31+ cells, 5% were Lin− cells, and 63% expressed B-220, 10% CD3e+, 2%
Ter-119+, 28% CD11b+, and 29% Gr-1+, respectively (Figure 1C). Virtually all (> 99%)
mBM-CD31+ cells expressed CD45 (Figure 1C), suggesting that the CD31+ cells are
hematopoietic cells, but not ECs, existing in BM. Among myelomonocytic CD31+ cells
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(CD11b- or Gr-1-expressing CD31+ cells), only 9% were Ly-6g+ (Figure 1D), suggesting
that a majority of myelomonocytic CD31+ cells are monocytes.
Next, we explored whether mBM-MNCs express other endothelial cell markers, and if so, to
determine whether these cells express higher levels of CD31, thereby representing more
highly angiogenic or vasculogenic cells. FACS analysis showed that mBM-MNCs which
expressed various EC markers also co-expressed CD31 at the following rates: VE-cadherin
(VE-cad), 77%, Flk-1 (VEGFR-2), 63%, Tie2, 76% and von Willebrand factor (vWF), 87%
(Figure 1E). Triple staining with CD45 antibody, a pan-hematopoietic cell marker, showed
that the majority of cells double-positive for CD31 and any of the EC markers also
expressed CD45 (Figure 1F), suggesting that these cells are hematopoietic in origin rather
than circulating mature ECs. Human BM-derived CD31+ (hBM-CD31+) cells also had
similar hematopoietic and endothelial characteristics. FACS analysis showed that about 35
to 50% of hBM-MNCs expressed CD31 (Online Figure IA), and that CD31 was expressed
in 42% of CD19+ cells (B cells), 46% of CD3+ cells (T cells), 67% of CD14+ cells, and 76%
of CD11b+ cells (Online Figure IB). Among CD31+ cells, 19% expressed CD19, and 39%,
33%, and 29% were CD3+, CD14+, and CD11b+, respectively (Online Figure IC). Similar to
mBM-CD31+ cells, almost all hBM-CD31+ cells expressed CD45 (Online Figure IC),
indicating their hematopoietic, but not EC, identity. Again, similar to the mouse data, a
majority of hBM cells expressing EC markers expressed CD31: 90% in VE-cadherin+ BM
cells, 65% in KDR+ cells, 55% of Tie2+ cells, and 96% in vWF+ cells (Online Figure ID).
As in the mouse, most of the human BM cells double-positive for CD31 and any of the EC
markers expressed CD45 (Online Figure IE), indicating hematopoietic origin.
BM-CD31+ cells are enriched with higher levels of angiogenic and HSC/HPC genes
To determine whether mBM-CD31+ cells are enriched with angiogenic and hematopoietic
stem/progenitor genes, we carried out microarray analysis. We compared the gene
expression among CD31+, CD31−, Lin−CD31+, and Lin−CD31− cells using microarray and
gene set enrichment analysis (GSEA)26 to determine the enriched gene classes in each
population (Figure 2). The GSEA showed that pro-angiogenic, but not anti-angiogenic genes
were significantly upregulated in mBM-CD31+ cells as compared to mBM-CD31− cells
(Figure 2A). Furthermore, the expression levels of HSC/HPC-specific genes were also
significantly higher in mBM-CD31+ cells than in mBM-CD31− cells. Higher expression of
pro-angiogenic genes and HSC/HPC genes was also observed in Lin−CD31+ cells compared
to Lin−CD31− cells. These data suggest that CD31 is a marker for angiogenic cells and
HSCs/HPCs in both total BM cells and Lin− BM cells. Next, we further carried out leading-
edge subset analysis to identify the core pro-angiogenic genes that confer angiogenic
characteristics of CD31+ cells, and found that high expression levels of 22 pro-angiogenic
genes comprised the angiogenic phenotype of mBM-CD31+ cells (Figure 2B). The higher
expression levels of most of these genes were also confirmed by real-time RT-PCR analysis
(Figure 2B).
Similar experiments were performed for human BM-CD31+ and CD31− cells. GSEA
showed significantly higher expression of pro-angiogenic genes and HSC/HPC genes in
hBM-CD31+ cells as compared to hBM-CD31− cells (Figure 2C, D), indicating that
angiogenic cells and HSC/HPCs are enriched in the CD31+ fraction. The leading-edge
subset analysis identified high expression levels of 24 core pro-angiogenic genes, including
VEGF-A and angiopoietin-1, in hBM-CD31+ cells.
HSCs and HPCs are almost exclusively restricted to the BM-CD31+ cell population
We explored the expression of CD31 in HSCs and HPCs. Approximately 91% of LSK cells
in mouse BM, which include HSCs and multipotent progenitor cells (MPPs), express CD31
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(Figure 3A)20. Since it appears that the level of CD31 expression decreases as HSCs
undergo differentiation into mature hematopoietic cells, we examined the expression of
CD31 in cells of intermediate status, i.e. oligopotent progenitor cells such as common
lymphocyte progenitors (CLPs) and common myeloid progenitors (CMPs). As in LSK cells,
most CLPs and CMPs identified as Lin−IL-7Ra+c-KitlowSca-1lowThy-1.1−28 and
Lin−IL-7Ra−c-Kit+Sca-1−FcγRlowCD34+29 cells, respectively, expressed CD31 (Figure
3A), suggesting that CD31 expression is maintained from HSCs and MPPs to oligopotent
progenitor cells. To confirm that CD31+ cells include HSCs and HPCs, we performed an in
vitro clonogenic assay and an in vivo BMT experiment. As expected, colony forming units,
including BFU-E, CFU-GM, and CFU-GEMM, were almost exclusively observed among
mBM-CD31+ cells (Figure 3B,C). Transplantation of 1 × 105 mBM-CD31+ cells into
lethally irradiated mice rescued all of the mice (10/10), whereas transplantation of mBM-
CD31− cells saved only 20% of the mice (2/10) (Figure 3D). In experiments with human
BM-MNCs, we found that cells expressing CD34 and CD133 were enriched in the CD31+
fraction (Online Figure IIA). Furthermore, CD31 was expressed in 99.8% of CD34+CD133+
cells and 89% of CD34+CD133− cells (Online Figure IIB), suggesting that HSCs and most
HPCs are included in the CD31+ cell population. Taken together, these results indicate that
HSCs and HPCs in both mice and humans exist almost exclusively in the CD31+ fraction.
EPCs are cultured from the CD31+, but not CD31− cell fraction
We determined whether mBM-CD31+ cells show endothelial differentiation potential in
vitro. First, conventional early EPC culture conditions were applied to CD31+ and CD31−
cells, and EPCs were identified by DiI-ac-LDL uptake and binding to BS-1 lectin1, 30.
Surprisingly, such EPCs were exclusively cultured from mBM-CD31+ cells, but not from
mBM-CD31− cells (Figure 4A, B). When the CD31+ cells were cultured for 8 or 9 days in
EGM-2 media supplemented with additional VEGF (50 ng/ml), the adherent cells expressed
vWF, Flk-1, VE-cadherin, and CD31, indicating an EC phenotype (Figure 4C). Similarly,
the early EPC assay using human BM cells showed that EPCs were cultured almost
exclusively from hBM-CD31+, but not hBM-CD31− cells (Online Figure IIIA). When hBM-
CD31+ cells were cultured in EGM-2 with 20% FBS for 6 days, the cells also underwent EC
phenotypic changes such that a majority of cells expressed endothelial-specific proteins such
as vWF, KDR, VE-cadherin, and CD31 (Online Figure IIIB). The CFU-Hill assay27 also
showed that CFU-Hill colonies were higher in hBM-CD31+ cells than hBM-CD31− cells
(Online Figure IIIC).
BM-CD31+ cells improve hindlimb ischemia and increase vascularity
To examine the therapeutic effects and vascularizing capacity of mBM-CD31+ cells in vivo,
we intramuscularly transplanted mBM-CD31+ cells into mice in a hindlimb ischemia model.
Nude mice were initially used, because 60 to 100% of nude mice lose all or part of their
hindlimbs following surgery, providing unambiguous results on the therapeutic efficacy of
transplanted cells17. In contrast, C57BL/6 mice spontaneously recover their blood flow to
near normal levels within four weeks, making it difficult to evaluate the therapeutic effects
of the treatment. mBM-CD31+ cells injected into nude mice prevented limb loss in 6 out of
7 mice (86%), whereas mBM-CD31− cells and PBS treatment rescued limbs in only 1 out of
7 and 0 out of 7 mice, respectively (Figure 5A). LDPI analysis also revealed that mBM-
CD31+ cell transplantation resulted in 1.8- and 2.4-fold enhanced blood flow compared to
mBM-CD31− cell- and PBS-treated controls, respectively (Figure 5C, D, mBM-CD31+ vs.
mBM-CD31− and PBS, 33 ± 2 vs. 43 ± 7 and 79 ± 5%, P < 0.01). We tested the therapeutic
effects again in C57BL/6 mice by injecting cells intramuscularly to increase the
engraftment. Again, mBM-CD31+, but not mBM-CD31− cell-injected mice showed
significantly improved perfusion in the hindlimb at day 14 compared to the PBS treated
mice (P < 0.01) (Online Figure IVA, B). In addition, injection of human BM-CD31+ cells
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into nude mice with hindlimb ischemia showed similar therapeutic effects represented by
higher limb salvage at 3 weeks (Online Figure VA, B) and 1.5- to 2.4-fold higher blood flow
in the hindlimb over 1 to 3 weeks than hBM-CD31− cells and PBS (Online Figure VC, D).
We also compared the therapeutic effects of the CD31+ cells with well characterized other
BM cell subpopulations on the recovery of hindlimb ischemia and found that there was no
difference in the capability to recover hindlimb ischemia among the CD31+ cells, CD34+
cells18, 24, CD34−CD31+ cells, and cultured EPCs10, 17 (Online Figure VI). The therapeutic
effects of CD31+ cells were significantly higher compared to total mononuclear cells
(Online Figure VII). To determine the therapeutic effects of HSC/HPCs included in CD31+
cells, mouse Lin−CD31+ cells and Lin+CD31+ cells were compared. The therapeutic effects
of these two subpopulations was not significantly different (Online Figure VIII), suggesting
that the therapeutic effects of CD31+ cells are attributable to both subpopulations.
To determine whether the CD31+ cells are still effective in subjects having cardiovascular
risk factors, we tested the therapeutic effect of the CD31+ cells isolated from ApoE-KO
mice fed a high-fat diet, a well known atherosclerosis model. We found no difference in the
therapeutic effects between the CD31+ cells derived from normal mice and ApoE-KO mice,
whereas the effects of CD31− cells derived from ApoE-KO mice were significantly lower
compared to CD31+ cells derived from normal or ApoE-KO mice (Online Figure IX).
To determine the effects of the CD31+ cells on neovascularization, we counted the number
of capillaries in the hindlimb muscles. mBM-CD31+ cell-injected nude mice showed 2.2-or
2.3-fold higher capillary density than mBM-CD31−- and PBS-injected mice, respectively
(CD31+ vs. CD31, PBS; 947 ± 114 vs. 436 ± 53, 408 ± 47 capillaries/mm2, P < 0.05)(Figure
5E, F). The beneficial effects of mBM-CD31+ cell injection on capillary density were also
observed in C57BL/6 mice but with less prominence (Figure IVC, D). Similarly, injection of
hBM-CD31+ cells into nude mice with ischemic limbs resulted in 1.5- and 2.1-fold higher
capillary density compared to hBM-CD31− cells and PBS, respectively (P < 0.01 vs, hBM-
CD31− cells and PBS)(Online Figure VE, F). The capillary density was not significantly
different between the groups injected with CD34+ cells and CD34−CD31+ cells (Online
Figure X).
BM-CD31+ cells have higher engraftment potential than BM-CD31− cells
We examined the engraftment of the transplanted cells into ischemic muscles. For this, we
isolated C0D31+ and CD31− cells from GFP-transgenic mice and injected them into a
hindlimb ischemia model. Fluorescent microscopic examination showed that two weeks
after cell injection, GFP-positive cells were more abundant in the CD31+ group than in the
CD31− group (Figure 6A, Online Figure XI, Online Video 1, 2). To quantify the number of
engrafted cells, in a separate series of experiments, we enzymatically digested the hindlimb
muscles and determined the number of GFP-positive cells by flow cytometric analysis. This
analysis showed that the number of engrafted cells was 3.4-fold higher in the CD31+ group
than in the CD31− group (P < 0.05) (Figure 6B). To further investigate the mechanism
underlying this higher engraftment of mBM-CD31+ cells, we carried out in vitro adhesion
studies, in which we investigated the adhesion capability of the cells to representative
extracellular matrix (ECM) proteins of the muscle tissue. This adhesion assay revealed that
mBM-CD31+ cells displayed 5-, 10-, and 2-fold higher adhesion to collagen, laminin, and
vitronectin, respectively, compared to the mBM-CD31− cells (Figure 6C, D), indicating that
higher adhesion capacity may underlie the higher engraftment of mBM-CD31+ in vivo.
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BM-CD31+ cells induce vasculogenesis in vivo
We determined the vasculogenic potential of mBM-CD31+ cells in vivo, i.e., whether the
transplanted CD31+ cells can give rise to ECs. As the vasculogenesis of BM cells is
disputed, we used rigorous criteria to judge the incorporation of cells into blood vessels as
ECs. To track the transplanted cells, we isolated CD31+ and CD31− cells from the BM of
GFP-transgenic mice (Figure 7) and confirmed these findings again with DiI labeled cells
(Online Figure XII). To identify functional ECs, we intravenously injected ILB4, which
stains the luminal side of ECs in functioning blood vessels9. We also used high resolution
confocal microscopy and analyzed the images by Z-stacked three-dimensional (3D)
reconstruction and FACS analysis. The images showed that mBM-CD31+ cells were
incorporated into functional capillaries and displayed typical EC morphology (Figure 7A, B,
Online Video 3), indicating true vasculogenic potential of mBM-CD31+ cells. Then, we
quantified the number of vasculogenic cells derived from the transplanted mBM-CD31+
cells using flow cytometric analysis after enzymatic digestion of the hindlimb tissues9. ECs
were identified by in vivo perfusion of ILB4 and the transplanted cells were identified by
their intrinsic GFP fluorescence. The number of injected cells exhibiting ILB4 was 3.7-fold
higher in the CD31+ group than in the CD31− group (engrafted cells/total ILB4+ ECs,
mBM-CD31+ vs. mBM-CD31−, 3.3 ± 0.8 vs. 0.9 ± 0.3%, P < 0.05) (Figure 7C, D),
suggesting that vasculogenic cells are significantly enriched in the CD31+ population. As
CD31+ cells include HSCs, HPCs, and a fraction of myelomonocytic cells, all of which were
reported to have vasculogenic effects, we further investigated what fractions contribute to
the vasculogenic effect of the CD31+ cells. For this, we quantitatively evaluated the
vasculogenic effect of CD34+ cells (HSCs and HPCs) and CD14+ cells (myelomonocytic
cells) with CD34−CD31+ cells and CD14−CD31+ cells, respectively. The vasculogenic
effects of CD34+ and CD34−CD31+ cells were similar (Online Figure XIIIA, B), suggesting
that the CD34−CD31+ cell fraction also contains a significant number of vasculogenic cells.
Intriguingly, the vasculogenic effect of CD14−CD31+ cells were significantly higher than
CD14+ cells (Online Figure XIIIC, D), indicating that a considerable portion of
vasculogenic cells are enriched in non-myelomonocytic CD31+ cells. Together these results
suggest that CD31+ cells include novel vasculogenic cells that do not belong to known
vasculogenic populations: hematopoietic stem and progenitor cells (CD34) and
myelomonocytic cells (CD14).
Transplantation of BM-CD31+ cells upregulates angiogenic, anti-apoptotic, and
chemoattractant factors in ischemic hindlimbs
To investigate the effects of mBM-CD31+ cells transplanted into ischemic hindlimb, the
biological factors associated with neovascularization were measured by real-time RT-PCR
on adductor muscles harvested 1 week after treatment. Various angiogenic factors, such as
Fgf2, Plgf, Angpt1, Angpt2, Tgfb, and Il6, were more highly expressed in the mBM-CD31+
group compared to the CD31− and PBS groups (Figure 8). Interestingly, Angpt2 increased
by 400 fold, whereas Angpt1 increased by only 13 fold in the CD31+ group compared to the
PBS group. The relative predominance of Angpt2 over Angpt1 has been previously reported
to be an indicator of a pro-angiogenic milieu31. Furthermore, anti-apoptotic and angiogenic
factor Igf1 was significantly upregulated in the CD31+ group compared to the other groups.
A representative chemoattractant molecule, Cxcl12 (Sdf1a) was also significantly
upregulated in the CD31+ group compared to the other groups. Taken together, these
findings indicate that many representative biological factors associated with angiogenesis,
anti-apoptosis, and BM cell chemotaxis were significantly upregulated in the ischemic
muscles injected with mBM-CD31+ cells, supporting a paracrine role for CD31+ cells in the
improvement of hindlimb ischemia.
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Discussion
In this study, we report that CD31 is a unique marker of a full spectrum of non-endothelial
hematopoietic BM cells that are tightly associated with neovascularization, as evidenced by
high angiogenic properties, high adhesion capacity, exclusive HSC/HPC activity, and
vasculogenic ability. These versatile functions enable CD31+ cells to induce higher
therapeutic neovascularization and greater therapeutic effects on the repair of limb ischemia.
CD31+ cells are highly pro-angiogenic cells both in mouse and human BM. To our
knowledge, this is the first study to demonstrate, with the use of multiple objective analyses,
that a specific, unmanipulated cell population in BM is more highly angiogenic than others.
In GSEA analysis, we used a priori-defined gene sets to analyze the data since post hoc
examination of top-ranking genes can be subjective and prone to bias. The histologic
analysis of hindlimb tissues showed that incorporation of transplanted CD31+ cells into the
vasculature as ECs was significant, but accounted for only 3.3% of the total functional ECs.
However, CD31+ cell injection increased capillary density by 1.3-fold, implying that non-
vasculogenic effects of the transplanted CD31+ cells are a more dominant mechanism for
neovascularization. Compatible with these data, transplantation of CD31+ cells resulted in
global upregulation of multiple angiogenic, anti-apoptotic, and chemotactic factors in the
ischemic limb.
With regard to the vasculogenesis of BM cells, we provide unambiguous evidence for the
physical contribution of injected BM cells to endothelial cell generation. Some recent
studies have argued against the vasculogenic potential of externally injected BM cells,
particularly in cardiovascular models11. We assumed that much of this controversy
originated from the technical difficulties of confirming vasculogenesis or from the
difference in the experimental settings such as type of injected cells, the recipient
environment (animal models), or route of cell administration. Supporting our notion is the
fact that the data regarding the absence of differentiation of BM cells into endothelial cells
and cardiomyocytes came from studies using specific HSC populations and specific animal
models such as MI8, in which long-term engraftment and survival of transplanted cells is
expected to be low due to constant motion of the heart and little oxygen and nutrients
available for the transplanted cells. In fact, another paper refuting the transdifferentiation of
similar HSCs to cardiomyocytes did not mention the potential of endothelial
transdifferentiation of the same cells32. Other recent studies showing the direct contribution
of BM cells to new vasculature used several tumor models and BM transplantation3, 9.
Based on these observations, we hypothesized that postnatal vasculogenesis can occur
through BM cells, although it may not occur frequently and may not be the main cause of
the therapeutic effects of BM cells on cardiovascular disease. With the following extensive
and meticulous analyses, the use of both 3D reconstruction of confocal images, flow
cytometric analysis of the digested tissues, use of both chemical dye and GFP-transgenic
mice for cell targeting, and application of rigorous criteria, we were able to confirm that BM
cells, especially CD31+ cells, can generate significant numbers of ECs in ischemic tissues.
Thus, we were able to conclude that when an appropriate BM cell is introduced into a
specific environment (here, hindlimb ischemia), genuine vasculogenesis from BM cells can
occur. This idea can be further expanded to describe the differentiation into ECs as a
context-dependent phenomenon rather than an “all or none” event. This study provides
convincing evidence for the occurrence of vasculogenesis or endothelial differentiation by
externally injected BM cells in at least an ischemic vascular disease setting.
This study further revealed another novel mechanism underlying the observed therapeutic
effect, cell engraftment. The higher paracrine and vasculogenic effects of CD31+ cells may
be, at least in part, due to higher engraftment of the transplanted CD31+ cells. The
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mechanisms underlying the higher engraftment of CD31+ cells may be stronger adhesion of
CD31+ cells to the ECM, which prevents the transplanted cells from both anoikis (apoptosis
due to lack of adhesion to ECMs) and cell removal by the vascular system. The importance
of cell engraftment and cell survival for increasing therapeutic effects has been
demonstrated by previous studies which employed overexpression of the Akt pathway in
transplanted cells or application of heat shock prior to transplantation33, 34. This study
demonstrates, for the first time, that a certain native population of BM cells, CD31+ cells,
possesses higher engraftment capability upon transplantation. We also do not exclude
possible favorable effects of an immunomodulatory role of the CD31+ cells on therapeutic
effects. Given that CD31+ cells include B and T lymphocytes and other potential immune
related cells, CD31+ cells may exert an immunomodulatory function to reduce tissue
damage and augment tissue regeneration. We also showed that mouse and human HSCs and
HPCs are almost exclusively restricted to the CD31+ fraction. Although mouse HSCs have
been reported to express CD3120, it was not known whether human HSCs and mouse HPCs
do so as well. Our flow cytometric analysis, in vitro clonogenic assay, and short-term BM
transplantation studies demonstrated that almost all HSCs and HPCs both in mouse and
human BM are CD31+, and we propose CD31 to be a universal marker for HSCs and HPCs.
Since there have been reports showing the favorable effects of HSCs for ischemic
cardiovascular diseases18, 23, 24, 35, the enrichment of HSCs in the CD31+ fraction may
provide another advantage of using CD31+ cells for therapeutic purposes.
Our study provides compelling evidence for the therapeutic utility of CD31+ cells for
regenerating ischemic tissues. In earlier studies, the criteria to select a specific population
for therapeutic use was based on the two premises that HSC/HPCs or EPCs would have
higher differentiation potential to give rise to ECs, and that therapeutic effects are mainly
attributable to the vasculogenic effect of the transplanted cells. Thus, HSC/HPC or EPC
markers, such as Lin−c-kit+ 23, CD34+ 18, 24, CD133+ 35, and Hoechst dye exclusion (side
population)36, have been used to select therapeutically effective cells. However, given the
recent reports that therapeutic effects of BM cells in ischemia repair are mainly attributable
to humoral or angiogenic effects 16, 37, isolating more highly angiogenic and/or paracrine
cells may be a better option for cell therapy. In this respect, BM-CD31+ cells could serve as
a favored option for second-generation cell therapy, as CD31+ cells have several advantages
over other cell types. First, transplantable CD31+ cells can be prepared without ex vivo
culture, which is required for EPCs and mesenchymal stem cells. Second, CD31+ cells are
relatively abundant. Unlike CD133+ and CD34+ cells, it is unnecessary to collect a large
volume of BM or to mobilize BM cells. Third, CD31+ cells are safer; we did not observe
any of the adverse effects, such as aggravation of hindlimb ischemia38, calcification or
tumor formation, reported in the use of BM-MNCs38, whole BM cells39 or mesenchymal
stem cells40, respectively. However, given the recent reports showing a contribution of
CD31 to the development of atherosclerosis in abdominal aorta in an animal model41, close
monitoring is required when using CD31+ cells in atherosclerotic disease. Another concern
is the effects of the disease state on the function of CD31+ cells. Although CD31+ cells
derived from ApoE KO mice are therapeutically comparable to wild-type CD31+ cells, we
do not exclude the possibility that CD31+ cells derived from chronically ill patients with
multiple cardiovascular risk factors may be less efficacious. Together, this study suggests
that CD31+ cells could serve as a novel therapeutic option for treating ischemic vascular
diseases.
Novelty and Significance
What is known?
• Bone marrow (BM)-derived endothelial progenitor cells (EPCs), which are
cultured cells, were reported to have blood vessel-growing capability.
Kim et al. Page 9
Circ Res. Author manuscript; available in PMC 2011 September 3.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
• There has been controversy regarding the vasculogenic ability or direct
(trans)differentiation of BM-derived cells.
• CD31 is a traditional marker for endothelial cells and is also expressed in a
fraction of BM cells.
What new information does this article contribute?
• CD31 is a comprehensive marker to identify highly angiogenic and
vasculogenic cells among uncultured heterogeneous BM mononuclear cells
(MNCs) both in human and mouse.
• A fraction of BM-MNCs that express CD31 can contribute to blood vessel
formation by differentiation into endothelial cells.
• Human and mouse BM-derived CD31+ cell transplantation ameliorated the
effects of ischemia in a hindlimb ischemia model.
Cell therapy with BM cells has emerged as a new therapeutic option for treatment of
ischemic cardiovascular diseases. However, several important questions remain regarding
the therapeutic mechanism and choice of cells: whether BM cells directly contribute to
the generation of endothelial cells (vasculogenesis), and whether there is a marker to
identify cells possessing high blood vessel forming capabilities among uncultured
heterogeneous BM cells. In this study, we show for the first time that CD31 can serve as
a marker to identify highly angiogenic and vasculogenic cells among uncultured BM-
MNCs. We also provide evidence for the occurrence of adult vasculogenesis from BM-
CD31+ cells injected into ischemic tissue. We discovered that CD31+ cells showed
higher adhesion and engraftment properties and paracrine activities than CD31− cells and
are effective for treating ischemic vascular disease; however, the major therapeutic
mechanism(s) underlying the effects of CD31+ cells are independent of endothelial
differentiation of the transplanted cells. This study suggests that BM-CD31+ cells can be
a highly promising cell source for cell therapy to treat ischemic cardiovascular diseases.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Non-standard Abbreviations and Acronyms
CLPs common lymphocyte progenitors
CMPs common myeloid progenitors
ECM extracellular matrix
ECs endothelial cells
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EPCs endothelial progenitor cells
GSEA gene set enrichment analysis
HPCs hematopoietic progenitor cells
HSCs hematopoietic stem cells
LSK lineage− Sca-1+c-Kit+
MI myocardial infarction
MNCs mononuclear cells
MPPs multipotent progenitor cells
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Figure 1. Expression of CD31 in mouse BM-MNCs
BM-MNCs were isolated from 8–12 week-old C57BL/6J mice and subjected to flow
cytometric analysis. Green color represents isotype control. (A) Expression of CD31 in
mouse BM-MNCs (mBM-MNCs). (B) Each bar represents the percentage of CD31+ cells
among the specified cells. (C) Expression of lineage markers in mBM-CD31+ cells. (D)
Expression of Ly-6g in CD31+ myelomonocytic cells identified by the expression of either
CD11b or Gr-1. Most of the CD31+ myelomonocytic cells were Ly-6g−, suggestive of
monocytes. (E) Each bar represents the percentage of CD31+ cells among the EC marker-
expressing cells. (F) The majority of cells double positive for CD31 and EC markers were
also positive for CD45, indicating hematopoietic origin. N = 3 (A – F).
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Figure 2. Gene expression pattern reveals the angiogenic characteristics of BM-CD31+ cells
(A) Total RNA was isolated from mouse BM-CD31+, BM-CD31−, Lin−CD31+, and
Lin−CD31− cells and subjected to microarray. N=3. (B) The leading-edge subset of pro-
angiogenic genes upregulated in mBM-CD31+ cells compared to mBM-CD31− cells. (C)
Total RNA was isolated from human BM-CD31+ and CD31− cells and analyzed similarly
(D) The leading-edge subset of pro-angiogenic genes upregulated in hBM-CD31+ cells
compared to hBM-CD31− cells. In B and D, red characters represent the values with
statistically significant difference. N=3.
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Figure 3. Enrichment of hematopoietic stem and progenitor cells in the CD31+ fraction of mouse
BM
(A) FACS analysis was performed using mBM-MNCs. N = 3. (B, C) Colony forming units
in mBM cells were determined by methylcellulose culture. (B) Representative
photomicrographs of a colony forming unit assay. (C) The number of colony-forming units
was compared between mBM-CD31+ cells, mBM-MNCs or mBM-CD31− cells (**P <
0.01, ***P < 0.001 vs. CD31− cells; †P < 0.05, ††P < 0.01, †††P < 0.001 vs. MNCs, n = 3).
(D) 1 × 105 mBM-CD31+, CD31− cells, or PBS were injected into lethally irradiated mice
and the survival was recorded (n = 10). Bars: B, 100 μm.
Kim et al. Page 16
Circ Res. Author manuscript; available in PMC 2011 September 3.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Figure 4. Differentiation of mBM-CD31+ cells into an endothelial cell phenotype in vitro
(A,B) mBM-CD31+ or -CD31− cells were cultured for four days in EGM-2 media, and cells
were incubated with DiI-acLDL and stained with FITC-conjugated BS-1 lectin and DAPI.
Cells triple-positive for DAPI, acLDL, and BS-1 lectin were counted as EPCs. (B, ***P <
0.001, n = 6 – 7). (C) mBM-CD31+ cells were induced to differentiate into ECs. The
cultured CD31+ cells exhibited multiple EC markers including vWF, Flk-1, CD31, and VE-
cad. Bars: A, 100 μm; C, 20 μm.
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Figure 5. Increase in blood flow and capillary density in ischemic hindlimb treated with mBM-
CD31+ cells
Two weeks after intravenous injection of mBM-CD31+ or -CD31− cells into athymic mice
with ischemic hindlimbs, the limb salvage (A, B), blood perfusion (C, D), and capillary
density (E, F) were investigated. (A - B) Representative photographs of the limbs (A) and
limb salvage rate (B)(n = 7) (C - D) Representative laser Doppler perfusion images (C) and
quantitation of blood perfusion (D, **P < 0.01, n = 3). (E, F) Capillary density counted after
ILB4 staining. Representative photomicrographs showing capillaries in the different
treatment groups (E). Quantitative analysis of capillary density (F, **P < 0.01, n = 5). Bars:
100 μm.
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Figure 6. Higher engraftment and adhesion capacity of mBM-CD31+ cells
(A, B) Microscopic and FACS analyses of the engrafted cells. The CD31+ and CD31− cells
isolated from GFP mice were intramuscularly injected into ischemic hindlimbs. Two weeks
later, the engrafted cells in the hindlimbs were examined by confocal microscopic (A) and
flow cytometric (B) analysis (*P < 0.05, n = 5). (C, D) The representative images and
quantitative analysis of the adhesion assay. CD31+ and CD31− cells were plated onto dishes
with various ECM proteins and the number of adherent cells was determined by fluorescent
microscopy (*P < 0.05, n = 3 – 5). Bars: A, 50 μm; C, 100 μm.
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Figure 7. Vasculogenesis in the ischemic hindlimb tissue
mBM-CD31+ or -CD31− cells were isolated from GFP mice and intramuscularily injected
into ischemic hindlimbs. One (A-B) or two weeks (C,D) after the transplantation, mice were
intravenously injected with Alexa 647-conjugated ILB4. (A-B) Representative confocal
images. Blue, DAPI (nuclei); green, GFP (CD31+ cells); red, ILB4 staining. (A and B)
Orthogonal (A) and 3D-projection (B) views with corresponding single color images.
Transplanted CD31+ cells incorporated into functional blood vessels as ECs. (C)
Representative FACS analysis of digested hindlimb tissue to determine ECs derived from
the transplanted cells. (D) The number of ECs derived from injected cells. (*P < 0.05, n =
5). Bars: A and B, 10 μm.
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Figure 8. Upregulation of various paracrine or humoral factors in ischemic hindlimbs injected
with mBM-CD31+ cells
The hindlimb tissues were harvested 7 days after cell transplantation and subjected to qRT-
PCR. Gene levels were normalized to GAPDH. Data are presented as fold differences
compared to the value of the PBS group (n = 4 per group, *P < 0.05, **P < 0.01, ***P <
0.001).
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